NanoViricides, Inc. (NYSE American: NNVC) highlighted the potential need for broad-spectrum antiviral treatments following a recent Andes hantavirus incident aboard a cruise ship. The company pointed to its clinical-stage antiviral candidate NV-387 as a potential therapeutic platform for emerging viral threats. NV-387 has completed a Phase I safety and tolerability trial in healthy volunteers with no reported adverse events, and has demonstrated effectiveness in animal models involving multiple viral lung infections, including coronaviruses, RSV, influenza, monkeypox, and measles.
According to the company, NV-387 is a unique broad-spectrum antiviral drug that targets a broad range of pathogenic viral infections. The drug candidate is being developed as a treatment for RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections. Additionally, NV-387 has shown efficacy in animal models for monkeypox, smallpox, and measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
The Andes hantavirus incident underscores the ongoing threat of emerging infectious diseases and the importance of developing antiviral platforms with broad-spectrum activity. Hantaviruses can cause severe respiratory illness, and there are currently no approved vaccines or specific treatments for hantavirus infections. NanoViricides' NV-387, with its demonstrated activity against multiple viruses, could potentially address such unmet medical needs.
NanoViricides is a clinical-stage company that creates special purpose nanomaterials for antiviral therapy. In addition to NV-387, the company is developing NV-HHV-1 for the treatment of all herpesvirus infections, including HSV-1, HSV-2, VZV shingles, and chickenpox. The company cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to dependence on external collaborators and consultants.
The recent event highlights the importance of continued investment in antiviral research and development. As global travel and connectivity increase, the risk of emerging viral outbreaks remains high. Broad-spectrum antivirals like NV-387 could play a crucial role in pandemic preparedness and response, offering a therapeutic option against a wide range of viruses.
For more information about NanoViricides, visit the company’s newsroom at https://ibn.fm/NNVC. The full press release regarding this announcement is available at https://ibn.fm/OYkof.
